Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mesenchymal stem cell secretome (Indonesia University)
- Development stage
- Unknown
- Lead developer
- Universitas Indonesia
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This is a cell-free biologic therapy developed by Indonesia University (Universitas Indonesia) for the treatment of severe COVID-19. The therapy consists of the secretome harvested from hypoxia-conditioned mesenchymal stem cells (MSCs) using a tangential flow filtration (TFF) strategy. This secretome contains a complex mixture of bioactive molecules, including anti-inflammatory cytokines such as Interleukin-10 (IL-10) and Transforming Growth Factor-beta (TGF-β), as well as growth factors like Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF). The treatment is designed to mitigate the cytokine storm and systemic inflammation associated with severe SARS-CoV-2 infection through its immunomodulatory, anti-apoptotic, and pro-angiogenic properties. Clinical evaluation in a Phase 3 randomized, placebo-controlled trial conducted in Indonesia demonstrated that the MSC secretome could effectively control inflammation with a favorable safety profile in hospitalized patients.
- Other names
- MSC secretomeHypoxia-conditioned MSC secretomeSecretome-mesenchymal stem cellInjection of secretome - mesenchymal stem cell
02
Targets
IL10RA (Interleukin-10 Receptor)PDGFRA (Platelet-derived growth factor receptor alpha)TGFBR (TGF-beta receptor)VEGFR (VEGFR family)PDGFR (PDGFR family)
Beyond the preview
Go deeper on Mesenchymal stem cell secretome (Indonesia University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mesenchymal stem cell secretome (Indonesia University).